938444-93-0

Solubility:DMSO

Storage:-20c two years

Biologieal

D-106669 has been disclosed with a submicromolar inhibition of PI3Ka.Its pyridopyrazine core,substituted by an anilino residue,has been the base scaffold of a more advanced derivative AEZS-126.this molecule is described as selectitively inhibiting class I PI3K and showed some activity in A549(lung cancer)xenografts mouse model at oral dose of 30mg/kg twice daily

Reference

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway